Clinical Trial Supply And Logistics Market to Reach US$ 12.4 Bn by 2030

The worldwide Clinical Trial Supply And Logistics market measurement is anticipated to achieve USD 12.4 billion by 2030 and is anticipated to increase at a CAGR of 9.1% from 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38699

Growth Factors

The market growth is attributed to the increasing R&D expenditure by pharmaceutical and biopharmaceutical firms and the rising number of clinical trials conducted globally. Furthermore, the market is mostly driven by technological advancements in the supply chain. The growing complexity in clinical studies and increased competition among players are factors responsible for the adoption of new technologies in supply chain management.

clinical trials have increased due to the rising demand for the Covid-19 vaccine. According to the WHO, more than 80 vaccines are currently being studied in clinical trials, with over 180 in the pre-clinical stage. There would be a challenge for logistics related to timelines and access to a large population.

By Service Analysis

The logistics and distribution segment led the market and accounted for a revenue share of over 20.0% in 2020. The segment is also anticipated to register the fastest growth rate throughout the forecast period. This is due to the globalization of clinical trials, an increase in the number of trials involving temperature-sensitive products, and the highly regulated structure of the industry.

Technological developments are positively impacting the global market, both on the inbound and outbound sides. As additional Point of Care (POC) diagnostic tools are developed, there would be a trend toward performing more and more local analyses and transferring less blood, tissue, urine, and other samples to a central site for examination in the future.

Advances in smart packaging solutions, such as active and passive thermo-regulated products, ensure that shipments stay within suitable temperature ranges while en-route and in storage, protecting the contents of the shipment

By Phase Analysis

The phase III segment held the largest revenue share of over 40.0% in 2020. This is primarily due to a rise in the number of patients enrolled in phase III trials. Investigators in phase III studies compare the novel treatment’s safety and efficacy against the current standard of care.

Phase II clinical trials had the highest number of projects in 2020 and this trend is expected to continue owing to increasing investments in R&D by industry and non-industry sponsors.

By Therapeutic Area Analysis

The cardiovascular diseases segment led the largest revenue share of over 25.0% in 2020. This is due to the large and growing number of cardiovascular research studies and the growing number of companies focused on bringing innovative drugs to the market.

The oncology segment held the second-largest share in 2020. This is due to the high prevalence of cancer. In 2018, cancer was the second biggest cause of death around the world, accounting for 9.6 million fatalities, or one in every six deaths. 

By End-user Analysis

Based on end-user, the pharmaceuticals segment led the market and accounted for over 40.0% share in 2020. This is due to the increased number of clinical studies conducted by pharmaceutical companies and R&D investments by these companies. Besides, the globalization of clinical trials is supporting market growth.

The biologicals segment is projected to expand at the fastest growth rate of 7.3% over the forecast period. This may be largely attributed to the increasing demand for biological products, such as cell and gene therapies, and vaccines and the growing investments in product development

By Regional Analysis

North America held the global market with a share of over 35.0% in 2020. An increase in the number of clinical trials conducted by pharmaceutical companies drives the market in the region. According to ClinicalTrials.gov, the U.S. performs the highest number of clinical trial operations per year.

Asia Pacific is anticipated to register the fastest growth rate of7.8% throughout the forecast period. The region has access to a large and diversified patient pool, cheaper recruitment costs, and favorable policies that make Asia Pacific desirable for clinical studies.

Key Players

  • Piramal Pharma Solutions
  •  UDG Healthcare
  • DHL
  • FedEx
  •  Movianto
  • Packaging Coordinators Inc.
  • Thermo Fisher Scientific (Patheon)
  • Catalent, Inc.
  • Parexel
  • Almac Group
  • Marken

Market Segmentation

  • Service
    • Logistics & Distribution
    • Storage & Retention
    • Packaging, Labeling, and Blinding
    • Manufacturing
    • Comparator Sourcing
    • Other Services (Solutions, Ancillary Supply)
  • Phase
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • End-user
    • Pharmaceuticals
    • Biologicals
    • Medical Device
  • Therapeutic Area
    • Oncology
    • Cardiovascular Diseases
    • Respiratory Diseases
    • CNS and Mental Disorders
    • Others
  • Regional
    • North America
      • U.S
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
    • Asia Pacific
      • Japan
      • China
      • India
      • Australia
      • South Korea
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Colombia
      • Chile
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
      • Iran
      • Israel

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38699

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and End-user Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Clinical Trial Supply And Logistics Market, By Service

7.1.  Clinical Trial Supply And Logistics Market, by Service, 2021-2030

7.1.1.    Logistics & Distribution

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Storage & Retention

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Packaging, Labeling, and Blinding

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Manufacturing

7.1.4.1.        Market Revenue and Forecast (2017-2030)

7.1.5.    Comparator Sourcing

7.1.5.1.        Market Revenue and Forecast (2017-2030)

7.1.6.    Other Services (Solutions, Ancillary Supply)

7.1.6.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Clinical Trial Supply And Logistics Market, By Phase

8.1.  Clinical Trial Supply And Logistics Market, by Phase, 2021-2030

8.1.1.    Phase I

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Phase II

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Phase III

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Phase IV

8.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Clinical Trial Supply And Logistics Market, By End-user

9.1.  Clinical Trial Supply And Logistics Market, by End-user, 2021-2030

9.1.1.    Pharmaceuticals

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Biologicals

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Medical Device

9.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Clinical Trial Supply And Logistics Market, By Therapeutic Area

10.1.        Clinical Trial Supply And Logistics Market, by Therapeutic Area, 2021-2030

10.1.1.  Oncology

10.1.1.1.      Market Revenue and Forecast (2017-2030)

10.1.2.  Cardiovascular Diseases

10.1.2.1.      Market Revenue and Forecast (2017-2030)

10.1.3.  Respiratory Diseases

10.1.3.1.      Market Revenue and Forecast (2017-2030)

10.1.4.  CNS and Mental Disorders

10.1.4.1.      Market Revenue and Forecast (2017-2030)

Chapter 11.      Global Clinical Trial Supply And Logistics Market, Regional Estimates and Trend Forecast

11.1.        North America

11.1.1.  Market Revenue and Forecast, by Service (2017-2030)

11.1.2.  Market Revenue and Forecast, by Phase (2017-2030)

11.1.3.  Market Revenue and Forecast, by End-user (2017-2030)

11.1.4.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.1.5.  U.S.

11.1.5.1.      Market Revenue and Forecast, by Service (2017-2030)

11.1.5.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.1.5.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.1.5.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.1.6.  Rest of North America

11.1.6.1.      Market Revenue and Forecast, by Service (2017-2030)

11.1.6.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.1.6.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.1.6.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.2.        Europe

11.2.1.  Market Revenue and Forecast, by Service (2017-2030)

11.2.2.  Market Revenue and Forecast, by Phase (2017-2030)

11.2.3.  Market Revenue and Forecast, by End-user (2017-2030)

11.2.4.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.2.5.  UK

11.2.5.1.      Market Revenue and Forecast, by Service (2017-2030)

11.2.5.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.2.5.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.2.5.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.2.6.  Germany

11.2.6.1.      Market Revenue and Forecast, by Service (2017-2030)

11.2.6.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.2.6.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.2.6.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.2.7.  France

11.2.7.1.      Market Revenue and Forecast, by Service (2017-2030)

11.2.7.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.2.7.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.2.7.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.2.8.  Rest of Europe

11.2.8.1.      Market Revenue and Forecast, by Service (2017-2030)

11.2.8.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.2.8.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.2.8.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.3.        APAC

11.3.1.  Market Revenue and Forecast, by Service (2017-2030)

11.3.2.  Market Revenue and Forecast, by Phase (2017-2030)

11.3.3.  Market Revenue and Forecast, by End-user (2017-2030)

11.3.4.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.3.5.  India

11.3.5.1.      Market Revenue and Forecast, by Service (2017-2030)

11.3.5.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.3.5.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.3.5.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.3.6.  China

11.3.6.1.      Market Revenue and Forecast, by Service (2017-2030)

11.3.6.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.3.6.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.3.6.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.3.7.  Japan

11.3.7.1.      Market Revenue and Forecast, by Service (2017-2030)

11.3.7.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.3.7.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.3.7.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.3.8.  Rest of APAC

11.3.8.1.      Market Revenue and Forecast, by Service (2017-2030)

11.3.8.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.3.8.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.3.8.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.4.        MEA

11.4.1.  Market Revenue and Forecast, by Service (2017-2030)

11.4.2.  Market Revenue and Forecast, by Phase (2017-2030)

11.4.3.  Market Revenue and Forecast, by End-user (2017-2030)

11.4.4.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.4.5.  GCC

11.4.5.1.      Market Revenue and Forecast, by Service (2017-2030)

11.4.5.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.4.5.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.4.5.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.4.6.  North Africa

11.4.6.1.      Market Revenue and Forecast, by Service (2017-2030)

11.4.6.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.4.6.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.4.6.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.4.7.  South Africa

11.4.7.1.      Market Revenue and Forecast, by Service (2017-2030)

11.4.7.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.4.7.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.4.7.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.4.8.  Rest of MEA

11.4.8.1.      Market Revenue and Forecast, by Service (2017-2030)

11.4.8.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.4.8.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.4.8.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.5.        Latin America

11.5.1.  Market Revenue and Forecast, by Service (2017-2030)

11.5.2.  Market Revenue and Forecast, by Phase (2017-2030)

11.5.3.  Market Revenue and Forecast, by End-user (2017-2030)

11.5.4.  Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.5.5.  Brazil

11.5.5.1.      Market Revenue and Forecast, by Service (2017-2030)

11.5.5.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.5.5.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.5.5.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

11.5.6.  Rest of LATAM

11.5.6.1.      Market Revenue and Forecast, by Service (2017-2030)

11.5.6.2.      Market Revenue and Forecast, by Phase (2017-2030)

11.5.6.3.      Market Revenue and Forecast, by End-user (2017-2030)

11.5.6.4.      Market Revenue and Forecast, by Therapeutic Area (2017-2030)

Chapter 12.  Company Profiles

12.1.              Piramal Pharma Solutions

12.1.1.  Company Overview

12.1.2.  Service Offerings

12.1.3.  Financial Performance

12.1.4.  Recent Initiatives

12.2.              UDG Healthcare

12.2.1.  Company Overview

12.2.2.  Service Offerings

12.2.3.  Financial Performance

12.2.4.  Recent Initiatives

12.3.              DHL

12.3.1.  Company Overview

12.3.2.  Service Offerings

12.3.3.  Financial Performance

12.3.4.  Recent Initiatives

12.4.              FedEx

12.4.1.  Company Overview

12.4.2.  Service Offerings

12.4.3.  Financial Performance

12.4.4.  Recent Initiatives

12.5.              Movianto

12.5.1.  Company Overview

12.5.2.  Service Offerings

12.5.3.  Financial Performance

12.5.4.  Recent Initiatives

12.6.              Packaging Coordinators Inc.

12.6.1.  Company Overview

12.6.2.  Service Offerings

12.6.3.  Financial Performance

12.6.4.  Recent Initiatives

12.7.              Thermo Fisher Scientific (Patheon)

12.7.1.  Company Overview

12.7.2.  Service Offerings

12.7.3.  Financial Performance

12.7.4.  Recent Initiatives

12.8.              Catalent, Inc.

12.8.1.  Company Overview

12.8.2.  Service Offerings

12.8.3.  Financial Performance

12.8.4.  Recent Initiatives

12.9.              Parexel

12.9.1.  Company Overview

12.9.2.  Service Offerings

12.9.3.  Financial Performance

12.9.4.  Recent Initiatives

12.10.           Almac Group

12.10.1.               Company Overview

12.10.2.               Service Offerings

12.10.3.               Financial Performance

12.10.4.               Recent Initiatives

Chapter 13.  Research Methodology

13.1.              Primary Research

13.2.              Secondary Research

13.3.              Assumptions

Chapter 14.  Appendix

14.1.              About Us

14.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38699

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com